Hetero, through its biologics arm Hetero Biopharma has been roped in as the manufacturing partner by the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), for producing Sputnik V the world's first registered vaccine against the novel coronavirus infection in India.
As per the agreement, Hetero Biopharma will be manufacturing over 100 million doses of the Sputnik V vaccine per year.
Editor’s Note: . Please make sure that you are subscribed to the TyroPharma Newsletter (*to Activate Subscription Verify Link in your E-Mail inbox*) to be notified of all of the latest & Upcoming Vacancies. Follow us on social media Facebook, Twitter, LinkedIn, WhatsApp, Telegram
